OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is approved as a subcutaneous injection 

Dosing schedules

 Bladder icon

Find dosing information to get patients with locally advanced, metastatic, or earlier-stage urothelial carcinoma started on therapy

Adjuvant Treatment of Urothelial Carcinoma1,2

INDICATIONS

INTRAVENOUS USE OPDIVO® (nivolumab) is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. View OPDIVO IV dosing schedule >

SUBCUTANEOUS USE OPDIVO Qvantig, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.

OPDIVO Qvantig Monotherapy
DOSING & SCHEDULE DURATION

600 mg nivolumab and 10,000 units hyaluronidase subcutaneous injection over 3-5 minutes q2w

OR

1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneous injection over 3-5 minutes q4w

Until disease recurrence or unacceptable toxicity for up to 1 year

No premedications are required.

Review the U.S. Full Prescribing Information for OPDIVO Qvantig.

1L Unresectable or Metastatic Urothelial Carcinoma1,2

INDICATIONS

INTRAVENOUS USE OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. View OPDIVO IV dosing schedule >

SUBCUTANEOUS USE OPDIVO Qvantig, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC.

OPDIVO Qvantig with cisplatin and gemcitabine
DOSING & SCHEDULE DURATION
Combination phase
900 mg nivolumab and 15,000 units hyaluronidase subcutaneous injection over 3-5 minutes in combination with cisplatin and gemcitabine on the same day q3w In combination with cisplatin and gemcitabine for up to 6 cycles
Monotherapy phase

600 mg nivolumab and 10,000 units hyaluronidase subcutaneous injection over 3-5 minutes q2w

OR

1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneous injection over 3-5 minutes q4w

After completing up to 6 cycles of combination therapy, administer as a single agent until disease progression, unacceptable toxicity, or up to 2 years from first dose

No premedications are required.

Review the U.S. Full Prescribing Information for OPDIVO Qvantig.

Locally Advanced or Metastatic Urothelial Carcinoma1,2

INDICATIONS

INTRAVENOUS USE OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. View OPDIVO IV dosing schedule >

SUBCUTANEOUS USE OPDIVO Qvantig, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

OPDIVO Qvantig Monotherapy
DOSING & SCHEDULE DURATION

600 mg nivolumab and 10,000 units hyaluronidase subcutaneous injection over 3-5 minutes q2w

OR

1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneous injection over 3-5 minutes q4w

Until disease progression or unacceptable toxicity

No premedications are required.

Review the U.S. Full Prescribing Information for OPDIVO Qvantig.

IV=intravenous; q2w=every 2 weeks; q4w=every 4 weeks.

IMARS icon
Treatment Modifications

See recommended dosing modifications for immune-mediated adverse reactions with OPDIVO, YERVOY, or OPDIVO Qvantig.

Clipboard with checklist icon
Preparation and Administration

Find instructions for preparation, administration, and storage for both OPDIVO infusions and OPDIVO Qvantig subcutaneous injections.

OPDIVO® (nivolumab) dosing guide icon
Dosing Guide

A guide to dosing intravenous OPDIVO and subcutaneous injection OPDIVO Qvantig.
 

References:

  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. OPDIVO Qvantig [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.


1506-US-2400780  04/25